These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24595134)

  • 1. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine.
    Tsuda Y; Saruwatari J; Yasui-Furukori N
    BMJ Open; 2014 Mar; 4(3):e004216. PubMed ID: 24595134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine.
    Haslemo T; Eikeseth PH; Tanum L; Molden E; Refsum H
    Eur J Clin Pharmacol; 2006 Dec; 62(12):1049-53. PubMed ID: 17089108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment.
    Lowe EJ; Ackman ML
    Ann Pharmacother; 2010 Apr; 44(4):727-32. PubMed ID: 20233914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
    Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
    Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of smoking behavior on clozapine blood levels - a systematic review and meta-analysis.
    Wagner E; McMahon L; Falkai P; Hasan A; Siskind D
    Acta Psychiatr Scand; 2020 Dec; 142(6):456-466. PubMed ID: 32869278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.
    Meltzer HY; Bobo WV; Roy A; Jayathilake K; Chen Y; Ertugrul A; Anil Yağcioğlu AE; Small JG
    J Clin Psychiatry; 2008 Feb; 69(2):274-85. PubMed ID: 18232726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Schwarz S; Schmid F; Hunger H; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2011 Jan; (1):CD006626. PubMed ID: 21249678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clozapine versus other atypical antipsychotics for schizophrenia.
    Asenjo Lobos C; Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Leucht S
    Cochrane Database Syst Rev; 2010 Nov; (11):CD006633. PubMed ID: 21069690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia.
    Zoccali R; Muscatello MR; Torre DL; Malara G; Canale A; Crucitti D; D'Arrigo C; Spina E
    Pharmacol Res; 2003 Oct; 48(4):411-4. PubMed ID: 12902213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors.
    Wu TH; Chiu CC; Shen WW; Lin FW; Wang LH; Chen HY; Lu ML
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1889-93. PubMed ID: 18796323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the in-vivo muscarinic cholinergic receptor availability in patients treated with clozapine and olanzapine.
    Raedler TJ
    Int J Neuropsychopharmacol; 2007 Apr; 10(2):275-80. PubMed ID: 16945161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risperidone versus other atypical antipsychotic medication for schizophrenia.
    Gilbody SM; Bagnall AM; Duggan L; Tuunainen A
    Cochrane Database Syst Rev; 2000; (3):CD002306. PubMed ID: 10908551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.
    Tuppurainen H; Kuikka JT; Viinamäki H; Husso M; Tiihonen J
    Psychiatry Clin Neurosci; 2009 Aug; 63(4):529-37. PubMed ID: 19496999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
    Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
    JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Schmid F; Hunger H; Schwarz S; Srisurapanont M; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Jan; (1):CD006625. PubMed ID: 20091600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine.
    Zullino DF; Delessert D; Eap CB; Preisig M; Baumann P
    Int Clin Psychopharmacol; 2002 May; 17(3):141-3. PubMed ID: 11981356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.